001052365 001__ 1052365
001052365 005__ 20260123203315.0
001052365 0247_ $$2doi$$a10.1111/ene.70103
001052365 0247_ $$2ISSN$$a1351-5101
001052365 0247_ $$2ISSN$$a1468-1331
001052365 0247_ $$2datacite_doi$$a10.34734/FZJ-2026-00963
001052365 037__ $$aFZJ-2026-00963
001052365 082__ $$a610
001052365 1001_ $$00000-0002-7296-4349$$aKonitsioti, Agni M.$$b0$$eCorresponding author
001052365 245__ $$aSuccessful Natalizumab Treatment of Two Female Individuals With Susac Syndrome
001052365 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
001052365 3367_ $$2DRIVER$$aarticle
001052365 3367_ $$2DataCite$$aOutput Types/Journal article
001052365 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769173888_30096
001052365 3367_ $$2BibTeX$$aARTICLE
001052365 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001052365 3367_ $$00$$2EndNote$$aJournal Article
001052365 500__ $$aOpen Access funding enabled and organized by Projekt DEAL.
001052365 520__ $$aBackground: Susac syndrome is a rare autoimmune endotheliopathy that affects the central nervous system, retina, and inner ear, characterized by encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. Due to the heterogeneity of its presentation, early diagnosis, and treatment remain challenging.Objective/methods: To evaluate the clinical outcomes and radiological responses in two patients with Susac syndrome treated with natalizumab in an off-label therapeutic approach, clinical assessments and serial magnetic resonance imaging (MRI) were performed over a follow-up period of up to 22 months to monitor disease progression and treatment response.Results: Both patients demonstrated clinical stabilization with reduced MRI and retinal angiography disease activity. Treatment was well tolerated, and no significant adverse events were reported during observation.Discussion: Natalizumab may constitute a potential off-label therapeutic for Susac syndrome. Further studies are warranted to assess its efficacy and safety in this rare condition.Keywords: DMT; MRI; neuroimmunology; neuroinflammation; neuroopthalmology; susac; vasculitis.
001052365 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001052365 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001052365 7001_ $$0P:(DE-HGF)0$$aGrajewski, Rafael$$b1
001052365 7001_ $$0P:(DE-HGF)0$$aSchlamann, Mark$$b2
001052365 7001_ $$0P:(DE-HGF)0$$aSchroeter, Michael$$b3
001052365 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b4$$ufzj
001052365 7001_ $$0P:(DE-HGF)0$$aWarnke, Clemens$$b5
001052365 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.70103$$gVol. 32, no. 3, p. e70103$$n3$$pe70103$$tEuropean journal of neurology$$v32$$x1351-5101$$y2025
001052365 8564_ $$uhttps://juser.fz-juelich.de/record/1052365/files/Euro%20J%20of%20Neurology%20-%202025%20-%20Konitsioti%20-%20Successful%20Natalizumab%20Treatment%20of%20Two%20Female%20Individuals%20With%20Susac%20Syndrome.pdf$$yOpenAccess
001052365 909CO $$ooai:juser.fz-juelich.de:1052365$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
001052365 9101_ $$0I:(DE-HGF)0$$60000-0002-7296-4349$$a UK Köln$$b0
001052365 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b4$$kFZJ
001052365 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001052365 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2022$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-12$$wger
001052365 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
001052365 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001052365 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001052365 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NEUROL : 2022$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
001052365 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
001052365 920__ $$lyes
001052365 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001052365 980__ $$ajournal
001052365 980__ $$aVDB
001052365 980__ $$aUNRESTRICTED
001052365 980__ $$aI:(DE-Juel1)INM-3-20090406
001052365 9801_ $$aFullTexts